Key result
Novel agents including SGLT-2i, GLP1-RA, and MRA significantly reduce the risk of cardiovascular events and chronic kidney disease progression in patients with kidney disease.
Highlights the prevailing gender gap and underrepresentation of women in recent landmark kidney trials evaluating novel agents such as SGLT-2i, GLP1-RA, and MRAs.
With the recent development of sodium glucose cotransporter-2 inhibitors (SGLT-2i), glucagon-like peptide-1 receptor agonists (GLP1-RA), and nonsteroidal mineralocorticoid receptor antagonists (MRA), there has been a surge of high-quality randomized controlled trials demonstrating substantial benefits of these agents for persons with kidney disease, after a period of relative stagnation.1 These novel agents significantly reduce the risk of cardiovascular events and/or chronic kidney disease progression; benefits have been demonstrated in patients with diabetic kidney disease; and specific to SGLT-2i, patients with nondiabetic kidney disease.
No takes yet. Share an insight, caveat, or question.
Vinson et al. (2022) conducted an editorial in Kidney disease. SGLT-2i, GLP1-RA, and MRA was evaluated. Novel agents including SGLT-2i, GLP1-RA, and MRA significantly reduce the risk of cardiovascular events and chronic kidney disease progression in patients with kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: